ClinicalTrials.gg
RecruitingNCT07003074Updated Jun 25, 2025

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

A Phase 3 interventional study of TQB2102 for Injection and Docetaxel combined + Trastuzumab +Pertuzumab in Breast Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 25 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
642
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited — 11 open to participants now, 16 under way, 8 of them phase 3. Breast Neoplasms · Sino Biopharmaceutical Limited.

Planned enrollment
2nd of 28
642 · median 138
Started
2025
with 6 others
Phase 3
11 of 28
5 open now
Primary completion
2029-07
later than 14 of 15 live
Registered
23rd of 28
by date

Among the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, this one is the 2nd largest by planned enrollment, is one of 7 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 23rd registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

11 of the 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Breast Neoplasms by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily enrolled in this study with good compliance
  • Age: 18-75 years old; Performance Status (ECOG PS) score: 0-1
  • positive, recurrent or invasive breast cancer confirmed by histopathology or cell pathology
  • Defined hormone receptor (HR) status
  • Has not received systemic anti-tumor therapy during the recurrence/metastasis stage (acceptable ≤ endocrine therapy)
  • If receiving (new) therapy, it is required that the time interval between the end of systemic therapy (excluding endocrine therapy) and the discovery of recurrence/metastasis be greater than 12 months
  • Have at least one according to 1.1 criteria;
  • Good major organ function

Exclusion criteria

Exclusion Criteria:

  • It is known that there is spinal cord compression or active central nervous system ;
  • Subjects with only skin and/or brain lesions as target lesions
  • Combined diseases and medical history

    1. Have had or currently have other malignant tumors within the past 5 years of randomization
    2. Unrelieved toxic reactions above Common Terminology Criteria (CTC) AE grade 1 caused by any previous treatment
    3. Received major surgical treatment, open , or significant traumatic injury within 4 weeks prior to randomization
    4. There are diseases that affect intravenous injection and venous blood collection
    5. There are congenital bleeding and coagulation disorders present
    6. An arterial/deep vein thrombosis event occurred within 6 months prior to the first administration
    7. Poor blood pressure control
    8. Suffering from significant cardiovascular disease
    9. There is an uncontrolled infection of ≥ CTC AE grade 2 within 14 days before the start of treatment
    10. History of interstitial lung disease/pneumonia (non infectious) requiring medication intervention in the past
    11. Individuals with moderate to severe pulmonary dysfunction/disease within 3 months prior to the first administration
    12. Active viral hepatitis with poor control
    13. Active syphilis infected individuals in need of treatment
    14. Individuals who are preparing for or have previously undergone bone marrow transplantation or solid organ transplantation
    15. or systemic or absorbable local hormone therapy are required to achieve immunosuppression
    16. History of immunodeficiency, including positivity or other acquired or congenital immunodeficiency diseases
    17. Urine routine shows urinary protein ≥++and confirms 24-hour urinary protein quantification>1.0 g
    18. Patients with renal failure requiring hemodialysis or peritoneal dialysis
    19. Poor control of diabetes
    20. Individuals with epilepsy who require treatment
    21. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders
  • Tumor related symptoms and treatment

    1. There is a third interstitial fluid accumulation or cancerous lymphangitis that cannot be controlled by drainage or other methods
    2. History of cumulative dose exposure to anthracyclines in the past
    3. Received radiation therapy within 3 weeks prior to the start of study treatment and endocrine therapy within 2 weeks prior to the start of study treatment
    4. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks before the start of the study treatment
  • Research treatment related

    1. Previously received antibody conjugate therapy consisting of topoisomerase I inhibitors,;
    2. Allergic to any research drug or any ingredient or in the drug;
    3. Individuals who experience severe reactions after using monoclonal antibodies;
    4. Participated in other clinical trials of anti-tumor therapy within 4 weeks before the start of the research treatment.
  • According to the researcher's judgment, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
642 participants (estimated)

Study arms

  • Experimental
    TQB2102 for Injection

    Administer by intravenous infusion, with a 21-day treatment cycle.

    Drug: TQB2102 for Injection

  • Active comparator
    Docetaxel combined + Trastuzumab +Pertuzumab

    Docetaxel: 75mg/m2, administered once every 3 weeks, intravenous infusion for 60 minutes, for a total of 6 cycles; Trastuzumab: The initial loading dose is 8mg/kg, and 6mg/kg is administered every 3 weeks thereafter; Pertuzumab: initial loading dose of 840mg, intravenous infusion for 60 minutes; Afterwards, administer 420mg every 3 weeks. After each infusion of pertuzumab, it is recommended to observe for 30-60 minutes. After the observation, trastuzumab or chemotherapy can be continued.

    Drug: Docetaxel combined + Trastuzumab +Pertuzumab

Interventions

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., PertuzumabStudies of PertuzumabPertuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.

    Time frame: Up to approximately 30 months

  2. Progression-Free Survival

    It refers to the time between enrollment and the occurrence of objective disease progression or death caused by various reasons (whichever occurs first).

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Overall Survival

    It refers to the time between enrollment and death caused by various reasons.

    Time frame: Up to approximately 30 months

  2. Duration of Remission

    The subjects with the best response determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as complete response (CR) or partial response (PR) are defined as the period from the first recorded tumor response to the first recorded disease progression or death from any cause, whichever occurs first.

    Time frame: Up to approximately 30 months

  3. The incidence of adverse events

    During the period from the signing of the informed consent form by the subjects to 28 days after the last dose of medication/initiation of new anti-tumor treatment (based on the first occurrence), the incidence of adverse events was recorded according to the common adverse event (AE) evaluation criteria of the National Cancer Institute (NCI CTC AE 5.0 version).

    Time frame: Up to approximately 52 months

  4. The severity of adverse events

    During the period from the signing of the informed consent form by the subjects to 28 days after the last dose of medication/initiation of new anti-tumor treatment (based on the first occurrence), the severity of adverse events was recorded according to the common AE evaluation criteria of the National Cancer Institute (NCI CTCAE 5.0 version).

    Time frame: Up to approximately 52 months

  5. Blood concentrations of the Antibody-Drug Conjugate (ADC) drug TQB2102

    To evaluate the pharmacokinetic (PK) profile of TQB2102 for injection in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2,,Cycle 4, Cycle 8and 15 minutes after the end of infusion for Cycle 2, Cycle 4, (21 days as a treatment cycle)

  6. The incidence of drug-resistant antibodies (ADA) and neutralizing antibodies (NAb)

    The incidence of drug-resistant antibodies (ADA) and neutralizing antibodies (NAb)

    Time frame: within 60 minutes prior to the start of infusion for Cycle 1, Cycle 2,,Cycle 4, Cycle 8, Cycle16,and before administration and 28 days (± 7 days), (21 days as a treatment cycle)

  7. Total antibodies

    To evaluate the pharmacokinetic (PK) profile of TQB2102 for injection in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2,,Cycle 4, Cycle 8and 15 minutes after the end of infusion for Cycle 2, Cycle 4, (21 days as a treatment cycle)

  8. The small molecule toxin TQ22723

    To evaluate the pharmacokinetic (PK) profile of TQB2102 for injection in subjects with HER2 low-expressing recurrent/metastatic breast cancer.

    Time frame: Within 1 hour prior to the start of infusion for Cycle 1, Cycle 2,,Cycle 4, Cycle 8and 15 minutes after the end of infusion for Cycle 2, Cycle 4, (21 days as a treatment cycle)

07

Study locations

1 of 25 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2029, 49 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 49 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 4, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2030
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07003074
Responsible party
Sponsor
First posted
Jun 4, 2025
Start date
Jun 23, 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Jun 25, 2025

Study contacts

Zhimin Shao, Doctor
Contact
szm@163.com
18017312288
Yongmei Yin, Doctor
Contact
ym.yin@hotmail.com
13951842727

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102

Start the discussion